Bigger sandbox for in silico tox

A consortium of companies and regulators could trigger a step change in how industry uses in silico toxicology to evaluate drug impurities and reduce the list of wet experiments required for regulatory submissions.

So far, regulators worldwide have ruled one experimental assay can be replaced by an in silico toxicology test: a screen for the likelihood drug impurities will induce DNA point mutations. The consortium’s goal is to replicate that success for 20 more toxicological endpoints. ...